Soki Kashima, MD, PhD
Associate Research ScientistAbout
Research
Publications
Featured Publications
Update on Biomarkers in Renal Cell Carcinoma.
Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D. Update on Biomarkers in Renal Cell Carcinoma. American Society Of Clinical Oncology Educational Book 2024, 44: e430734. PMID: 38207251, DOI: 10.1200/edbk_430734.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaCell carcinomaMetastatic renal cell carcinomaTumor intrinsic featuresImmune checkpoint inhibitorsRobust predictive biomarkersCheckpoint inhibitorsDurable responsesOverall survivalCare regimensPathological characteristicsPredictive biomarkersTherapeutic responseTreatment paradigmImmune systemHost factorsTranscriptional signatureGenomic alterationsTumor heterogeneityBiomarkersCarcinomaBiomarker discoveryInnovative technological approachesRegimensThe Changing Landscape of Immunotherapy for Advanced Renal Cancer
Kashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaCentral therapeutic strategyAdvanced renal cancerDurable clinical benefitImmune checkpoint inhibitorsImmunecheckpoint inhibitorsCheckpoint inhibitorsCytokine therapyImmunogenic tumorsMost patientsSystemic therapyClinical benefitCombination therapyCurrent therapiesInterleukin-2Renal cancerTherapeutic strategiesTherapyCarcinomaInhibitorsImmunotherapyPatientsInterferonCytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model
Kashima S, Maeda T, Masuda K, Nagano S, Inoue T, Takeda M, Kono Y, Kobayashi T, Saito S, Higuchi T, Ichise H, Kobayashi Y, Iwaisako K, Terada K, Agata Y, Numakura K, Saito M, Narita S, Yasukawa M, Ogawa O, Habuchi T, Kawamoto H. Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model. IScience 2020, 23: 100998. PMID: 32259478, PMCID: PMC7188741, DOI: 10.1016/j.isci.2020.100998.Peer-Reviewed Original ResearchCytotoxic T lymphocytesPatient-derived xenograft modelsRenal cell carcinomaXenograft modelSolid tumorsT cellsT lymphocytesCurrent adoptive T cell therapiesTherapeutic efficacyWT1-specific cytotoxic T lymphocytesAdoptive T cell therapyT-cell therapyPatient T cellsSolid tumor modelsModels of leukemiaOrthotopic xenograft modelAutologous settingWT1 antigenCell carcinomaTumor modelAllogeneic approachCell therapyTumor growthAntigen-SpecificIPS cellsRegeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes
Maeda T, Nagano S, Kashima S, Terada K, Agata Y, Ichise H, Ohtaka M, Nakanishi M, Fujiki F, Sugiyama H, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H. Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes. Molecular Therapy — Methods & Clinical Development 2020, 19: 250-260. PMID: 33102617, PMCID: PMC7566080, DOI: 10.1016/j.omtm.2020.09.011.Peer-Reviewed Original ResearchCytotoxic T lymphocytesTumor antigen-specific cytotoxic T lymphocytesT-iPSCsT cell receptorT cellsT lymphocytesWT1-specific cytotoxic T lymphocytesExogenous T-cell receptorsAdoptive T cell therapyT-cell receptor genesT-cell therapyPatient T cellsAllogeneic T cellsT cell-derivedPluripotent stem cellsTreatment failureTCR genesCell therapyCell receptorsStem cellsIPSCsPatientsCell linesDifferentiation capabilityCellsFaithful preclinical mouse models for better translation to bedside in the field of immuno-oncology
Saito R, Kobayashi T, Kashima S, Matsumoto K, Ogawa O. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. International Journal Of Clinical Oncology 2019, 25: 831-841. PMID: 31407168, DOI: 10.1007/s10147-019-01520-z.Peer-Reviewed Original ResearchConceptsPreclinical mouse modelsMouse modelPrediction of immune-related adverse eventsPreclinical settingExploration of combination therapiesImmune-related adverse eventsCancer cell line-derived xenograftsCell line-derived xenograftsAutochthonous tumor modelImmunologically humanized micePatient-derived-xenograftsPredictive biomarker developmentImmune checkpoint inhibitorsSuccess of immunotherapyMurine tumor cell linesMicroenvironment of human cancersPractice of cancer treatmentCheckpoint inhibitorsTumor cell linesHumanized miceImmune microenvironmentCombination therapyImmuno-oncologyClinical featuresPreclinical studies
2025
The Impact of Early Modification of Upfront Androgen Receptor Signaling Inhibitors on Survival Outcomes in Metastatic Hormone‐Sensitive Prostate Cancer
Narita S, Yanagisawa T, Hatakeyama S, Fukuokaya W, Urabe F, Fujita N, Sekine Y, Sato H, Okada S, Kashima S, Yamamoto R, Kobayashi M, Numakura K, Saito M, Tsushima E, Kimura T, Habuchi T, Group J. The Impact of Early Modification of Upfront Androgen Receptor Signaling Inhibitors on Survival Outcomes in Metastatic Hormone‐Sensitive Prostate Cancer. The Prostate 2025 PMID: 41195461, DOI: 10.1002/pros.70092.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen receptor signaling inhibitorsCastration-resistant prostate cancer-free survivalInverse probability of treatment weightingHormone-sensitive prostate cancerSurvival outcomesProstate cancerMetastatic hormone-sensitive prostate cancer patientsFactors associated with survival outcomesProstate cancer-free survivalSignaling InhibitorsOptimal managementEffectiveness of first-line treatmentInverse probability of treatment weighting analysisInitial dose reductionUpfront abiraterone acetateAndrogen deprivation therapyProgression-free survivalCancer-free survivalFirst-line treatmentFollow-up durationMulticenter cohort studyInverse probabilityProbability of treatment weightingDeprivation therapyDevelopment of ex vivo patient-derived models to uncover the role of the tumor immune microenvironment in renal cell carcinoma 4463
Gupta R, Kashima S, Moritz V, Sadak K, Ng M, Adeniran A, Humphrey P, Bosenberg M, Hurwitz M, Kenney P, Braun D. Development of ex vivo patient-derived models to uncover the role of the tumor immune microenvironment in renal cell carcinoma 4463. The Journal Of Immunology 2025, 214 DOI: 10.1093/jimmun/vkaf283.2144.Peer-Reviewed Original ResearchPatient-derived tumor modelsRenal cell carcinomaImmune checkpoint inhibitorsRCC tumor microenvironmentT cell functionTumor microenvironmentT cellsFlow cytometryCell carcinomaTreatment of metastatic renal cell carcinomaImpact of immune checkpoint inhibitorsAnti-PD-1 antibodyAnti-PD-1 treatmentMetastatic renal cell carcinomaCD8+ T cellsAnti-PD-1IFN-g productionCD8 T cellsRegulatory T cellsT-cell phenotypeTumor immune microenvironmentHematoxylin and eosin stainingImmune cell populationsT cell stimulationPatient-derived modelsMyeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma
Bi K, Kashima S, Camp S, Meli K, Saad E, Titchen B, Labaki C, Bakouny Z, Pimenta E, Park J, Shannon E, Fu J, Xirenayi S, Horst J, Lum L, Ishizuka J, Choueiri T, Braun D, Van Allen E. Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma. Immunity 2025, 58: 2814-2829.e9. PMID: 41175876, PMCID: PMC12616721, DOI: 10.1016/j.immuni.2025.10.013.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeRenal cell carcinomaTumor immune microenvironmentResistance to immunotherapyT cell killingIFNG signalingCell carcinomaMyeloid cellsIFN-stimulated genesMechanisms of resistance to immune checkpoint blockadeResistance to immune checkpoint blockadeRenal cell carcinoma tumor cellsImmune checkpoint blockade efficacyAdvanced renal cell carcinomaTumor cells in vitroAnti-VEGF therapyClinical trial cohortCells in vitroMultiple mechanismsEffect of IFNCheckpoint blockadeAnti-VEGFImmune checkpointsTrial cohortTumor cellsInhibition of Fatty Acid-Binding Protein 4 Limits High-Fat-Diet-Associated Prostate Tumorigenesis and Progression in TRAMP Mice
Huang M, Narita S, Sato H, Sekine Y, Kobayashi M, Kashima S, Yamamoto R, Koizumi A, Nara T, Numakura K, Saito M, Nanjo H, Ikezoe T, Habuchi T. Inhibition of Fatty Acid-Binding Protein 4 Limits High-Fat-Diet-Associated Prostate Tumorigenesis and Progression in TRAMP Mice. International Journal Of Molecular Sciences 2025, 26: 10621. PMID: 41226657, PMCID: PMC12607695, DOI: 10.3390/ijms262110621.Peer-Reviewed Original ResearchConceptsFatty acid binding protein 4TRAMP miceProstate cancerHigh-fat dietProstate tumorigenesisTumor progressionProgression of prostate cancerBody weightDecreased body weightTransgenic adenocarcinomaMouse prostateCytokine productionCytokine secretionInflammatory pathwaysInflammatory responseProstateProtein 4MiceTherapeutic targetCancerHF conditionsTumorigenesisChemical inhibitorsMetabolic regulationProgressionIGFBP2 alteration contributes to prostate cancer progression by modulating prostate stroma activation
Huang M, Narita S, Sato H, Sekine Y, Kobayashi M, Kashima S, Yamamoto R, Koizumi A, Nara T, Numakura K, Saito M, Nanjo H, Ikezoe T, Habuchi T. IGFBP2 alteration contributes to prostate cancer progression by modulating prostate stroma activation. Cell Communication And Signaling 2025, 23: 408. PMID: 41039587, PMCID: PMC12492507, DOI: 10.1186/s12964-025-02414-6.Peer-Reviewed Original ResearchConceptsProstate cancer progressionProstate cancerTumor cell progressionProstate stromal fibroblastsProstate cancer cellsActivity of IGFsTumor cell growthCytokines IL-6Prostatic stromaLNCaP cellsStroma activationStromal microenvironmentBinding protein 2Cell progressionTumor progressionPCa progressionProstateStromal fibroblastsIL-8IL-6Cancer progressionTGF-bProtein 2TumorStroma
Academic Achievements & Community Involvement
News
News
- July 16, 2025
Yale Researchers Develop Novel Antibody-RNA Therapy for Resistant Cancers
- September 23, 2024Source: OncLive
Dr Kashima on T-Cell Phenotypes Associated With ICI Response/Resistance in RCC
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
- May 31, 2024
2024 ASCO Conquer Cancer Grants & Awards Announced
Get In Touch
Contacts
Locations
Center of Molecular and Cellular Oncology
Lab
300 George Street, Fl 6th Floor, Ste Suite 6109
New Haven, CT 06511